Find Reports

Select Report Type

Reimbursement Review

Displaying 701 - 725 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Darunavir/cobicistat	Prezcobix	Darunavir/cobicistat	cdr_SR0381_Prezcobix.pdf cdr_complete_ SR0381_Prezcobix_Mar_20-15.pdf SR0381_Prezcobix_CL_Report_e.pdf SR0381_Prezcobix_PE_Report_e.pdf media:document:3ceeb6a7-4e2b-4c15-ae53-9bec3bf123c4	HIV Infection	List with criteria/condition	Complete	May 22, 2014	Mar 18, 2015	SR0381-000
Ledipasvir / Sofosbuvir	Harvoni	Ledipasvir / Sofosbuvir	cdr_SR0395_Harvoni.pdf cdr_complete_SR0395_Harvoni_Mar_20-15.pdf SR0395_Harvoni_CL_Report_e.pdf SR0395_Harvoni_PE_Report_e.pdf SR0395 Harvoni_PI_Submissions_e.pdf	Hepatitis C, chronic	List with criteria/condition	Complete	Sep 15, 2014	Mar 18, 2015	SR0395-000
Imbruvica for Chronic Lymphocy...	Imbruvica	Ibrutinib	pcodr-provfund_ibrutinib_imbruvica-CLL.pdf pcodr-ibrutinib-cll-sll-fn-rec.pdf pcodr-ibrutinib-cll-sll-fn-cgr.pdf pcodr-ibrutinib-cll-sll-fn-egr.pdf pcodr-ibrutinib-cll-sll-in-rec.pdf pcodr-ibrutinib-pagfdk.pdf pcodr-ibrutinib-fdk-janssen.pdf pcodr-ibrutinib-fdk-llsccllpag.pdf pcodr-ibrutinib-coi-llsc.pdf pcodr-ibrutinib-coi-cllpag.pdf pcodr-ibrutinib-cll-sll-fdk-lc.pdf pcodr-ibrutinib-cll-sll-coi-lc.pdf	Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 15, 2014	Mar 5, 2015	PC0043-000
Pasireotide diaspartate	Signifor	Pasireotide diaspartate	cdr_SR0372_Signifor.pdf cdr_complete_SR0372_Signifor_Feb-26-15.pdf SR0372_Signifor_CL_Report.pdf SR0372_Signifor_PE_Report.pdf SR0372 Signifor_PI_Submissions.pdf	Cushing’s disease	Do not list	Complete	Feb 27, 2014	Feb 24, 2015	SR0372-000
Ranibizumab	Lucentis	Ranibizumab	cdr_SR0373_Lucentis.pdf cdr_complete_SR0373_Lucentis_CNV_Feb-20-15.pdf SR0373_LucentisCNV_CL_Report_e.pdf SR0373_LucentisCNV_PE_Report_e.pdf SR0373_Lucentis_PI_Submissions_e.pdf	Myopic choroidal neovascularisation	List with criteria/condition	Complete	Feb 28, 2014	Feb 19, 2015	SR0373-000
Tocilizumab	Actemra	Tocilizumab	cdr_SR0374_Actemra SC.pdf cdr_complete_SR0374_Actemra_SC_Feb-23-15.pdf SR0374_ActemraSC_CL_Report.pdf SR0374_ActemraSC_PE_Report.pdf SR0374_Actemra SC_PI_Submissions.pdf	Arthritis, rheumatoid	List with criteria/condition	Complete	Mar 3, 2014	Feb 19, 2015	SR0374-000
Arzerra for Chronic Lymphocyti...	Arzerra	Ofatumumab	pcodr_profund_ofatumumab_arzerra_cll.pdf pcodr-arzerra-cll-fn-rec.pdf pcodr-arzerra-cll-fn-cgr.pdf pcodr-arzerra-cll-fn-egr.pdf pcodr-arzerra-cll-in-rec.pdf pcodr-arzerra-cll-pagfdk.pdf pcodr-arzerra-cll-fdk-gsk.pdf pcodr-arzerra-cll-coi-llsc.pdf pcodr-arzerra-cll-coi-cllpag.pdf	Chronic Lymphocytic Leukemia	Do not reimburse	Complete	Apr 14, 2014	Jan 29, 2015	PC0038-000
Macitentan	Opsumit	Macitentan	cdr_SR0364_Opsumit.pdf cdr_complete_SR0364_Opsumit_Jan-30-15.pdf SR0364_Opsumit_CL_Report_e.pdf SR0364_Opsumit_PE_Report_e.pdf SR0364_Opsumit_PI_e.pdf	Pulmonary arterial hypertension	List with clinical criteria and/or conditions	Complete	Dec 18, 2013	Jan 28, 2015	SR0364-000
Gazyva for Chronic Lymphocytic...	Gazyva	Obinutuzumab	pcodr-provfund_gazyva-cll.pdf pcodr-gazyva-cll-fn-rec.pdf pcodr-gazyva-cll-fn-cgr.pdf pcodr-gazyva-cll-fn-egr.pdf pcodr-gazyva-cll-in-rec.pdf pcodr-gazyva-cll-pagfdk.pdf pcodr-gazyva-cll-fdk-roche.pdf pcodr-gazyva-cll-fdk-lc.pdf pcodr-gazyva-cll-coi-lc.pdf pcodr-gazyva-cll-ptfdk.pdf pcodr-gazyva-cll-coi-llsc.pdf pcodr-gazyva-cll-coi-cllpag.pdf	Chronic Lymphocytic Leukemia	Reimburse	Complete	Aug 11, 2014	Jan 27, 2015	PC0041-000
Alogliptin	Nesina	Alogliptin	cdr_SR0368_Nesina.pdf cdr_complete_SR0368_Nesina_Jan-19-15.pdf SR0368_Nesina_CL_Report.pdf SR0368_Nesina_PE_Report.pdf SR0368_Nesina_PI_Submissions.pdf	Diabetes mellitus, type 2	Do not list	Complete	Jan 30, 2014	Jan 15, 2015	SR0368-000
Alogliptin Plus Metformin	Kazano	Alogliptin plus metformin	cdr_SR0367_Kazano.pdf cdr_complete_SR0367_Kazano_Jan-19-15.pdf SR0367_Kazano_PE_Report.pdf SR0367_Kazano_CL_Report.pdf SR0367_Kazano_PI_Submissions.pdf	Diabetes mellitus, type 2	Do not list	Complete	Jan 30, 2014	Jan 15, 2015	SR0367-000
Canagliflozin	Invokana	Canagliflozin	Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Diabetes mellitus, type 2	List with criteria/condition	Complete	Feb 24, 2014	Jan 15, 2015	SR0370-000
Umeclidinium/vilanterol	Anoro Ellipta	Umeclidinium/vilanterol	cdr_SR0371_Anoro_Ellipta.pdf cdr_complete_SR0371_Anoro_Ellipta_Jan-23-15.pdf SR0371_Anoro_Ellipta_PI_Submissions.pdf SR0371_Anoro_Ellipta_CL_Report_e.pdf SR0371_Anoro_Ellipta_PE_Report_e.pdf	Chronic obstructive pulmonary disease	List with criteria/condition	Complete	Feb 26, 2014	Jan 15, 2015	SR0371-000
Yervoy for First Line Advanced...	Yervoy	Ipilimumab	pcodr_profund_ipilimumab_yervoy_melanoma1stline.pdf pcodr-yervoy1st-fn-rec.pdf pcodr-yervoy1stsub-fn-cgr.pdf pcodr-yervoy1stsub-fn-egr.pdf pcodr-yervoy1stsub-in-rec.pdf pcodr-yervoy1stsub-pagfdk.pdf pcodr-yervoy1stsub-bms.pdf pcodr-yervoy1st-mncfdk.pdf pcodr-yervoy1st-coi-mnc.pdf	First Line Advanced Melanoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 15, 2014	Dec 22, 2014	PC0042-000
Aripiprazole	Abilify Maintena	Aripiprazole	cdr_SR0366_Abilify_Maintena.pdf SR0366_Abilify Maintena_CL_Report.pdf SR0366_Abilify Maintena_PE_Report.pdf SR0366_Abilify Maintena_PI_Submissions.pdf cdr_complete_SR0366_Abilify-Maintena_Dec-23-14.pdf	Schizophrenia	List with criteria/condition	Complete	Jan 6, 2014	Dec 19, 2014	SR0366-000
Indacaterol/glycopyrronium	Ultibro Breezhaler	Indacaterol/glycopyrronium	cdr_SR0369_Ultibro_Breezhaler.pdf cdr_complete_SR0369_Ultibro Breezhaler_Jan30_2015.pdf SR0369_Ultibro Breezhaler_PI.pdf SR0369_UltibroBreezhaler_CL_Report.pdf SR0369_UltibroBreezhaler_PE_Report.pdf	Chronic obstructive pulmonary disease	List with criteria/condition	Complete	Feb 3, 2014	Dec 19, 2014	SR0369-000
Icatibant	Firazyr	Icatibant	cdr_SR0375_Firazyr.pdf cdr_complete_SR0375_Firazyr_Dec-23-14.pdf SR0375_Firazyr_CL_Report.pdf SR0375_Firazyr_PE_Report.pdf	Hereditary angioedema	List with clinical criteria and/or conditions	Complete	Mar 4, 2014	Dec 19, 2014	SR0375-000
Ivacaftor	Kalydeco	Ivacaftor	cdr_SR0379_Kalydeco CF.pdf cdr_complete_SR0379_Kalydeco_Dec-23-14.pdf SR0379_KalydecoCF_CL_Report.pdf SR0379_KalydecoCF_PE_Report.pdf SR0379_Kalydeco_PI_Submissions_e.pdf	Cystic Fibrosis, CFTR gating mutations	List with criteria/condition	Complete	May 1, 2014	Dec 19, 2014	SR0379-000
Infliximab	Inflectra	Infliximab	TS0001-PsO-Updated-Streamlined-Rec.pdf cdr_SE0384_Inflectra.pdf cdr_complete_SE0384_Inflectra_Dec-23-14.pdf SE0384_Inflectra_SEB_Report.pdf SE0384 Inflectra_PI_Submissions.pdf	Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis	List with criteria/condition	Complete	Jun 17, 2014	Dec 19, 2014	SE0384-000
OnabotulinumtoxinA	Botox	OnabotulinumtoxinA	cdr_SR0362_Botox_OAB.pdf cdr_complete_SR0362_Botox-OAB_nov14_2014.pdf SR0362_BotoxOAB_CL_Report_e.pdf SR0362_BotoxOAB_PE_Report_e.pdf SR0362_Botox OAB_PI_Submissions_e.pdf	Urinary incontinence	List with criteria/condition	Complete	Nov 25, 2013	Nov 12, 2014	SR0362-000
Mirabegron	Myrbetriq	Mirabegron	cdr_SR0363_Myrbetriq.pdf cdr_complete_SR0363_Myrbetriq_nov14_2014.pdf SR0363_Myrbetriq_CL_Report_e.pdf SR0363_Myrbetriq_PE_Report_e.pdf SR0363_Myrbetriq_PI_Submissions_e.pdf	Overactive bladder	List with criteria/condition	Complete	Nov 27, 2013	Nov 12, 2014	SR0363-000
Aripiprazole	Abilify	Aripiprazole	cdr_SR0354_Abilify.pdf SR0354_AbilifyMDD_CL_Report_e.pdf SR0354_AbilifyMDD_PE_Report.pdf cdr_complete_SR0354_Abilify-MDD_Oct-24_2014.pdf	Depression, Major Depressive Disorder	Do not list	Complete	Oct 1, 2013	Oct 22, 2014	SR0354-000
Ustekinumab	Stelara	Ustekinumab	cdr_SR0359_Stelara.pdf cdr_complete_SR0359_Stelara_Oct-22-14.pdf SR0359_Stelara_PE_Report.pdf SR0359_Stelara_CL_Report.pdf SR0359_Stelara_PI_Submissions.pdf	Arthritis, psoriatic	Do not list at the submitted price	Complete	Oct 30, 2013	Oct 20, 2014	SR0359-000
Aflibercept	Eylea	Aflibercept	cdr_SR0361_Eylea.pdf cdr_complete_SR0361-000_eylea_october_22_2014.pdf SR0361_Eylea_CL_Report.pdf SR0361_Eylea_PE_Report.pdf SR0361_Eylea_PI_Submissions.pdf	Macular degeneration, age-related	List with criteria/condition	Complete	Nov 18, 2013	Oct 20, 2014	SR0361-000
Stiripentol	Diacomit	Stiripentol	cdr_SR0360_Diacomit.pdf cdr_complete_SR0360_Diacomit_October_20_2014.pdf sr0360_diacomit_cl_report.pdf sr0360_diacomit_pe_report.pdf	Dravet Syndrome	List with criteria/condition	Complete	Oct 30, 2013	Oct 16, 2014	SR0360-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 600

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 701 - 725 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
entrectinib	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 8, 2023	Reimbursement Review		Complete	PC0278-000
tezepelumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 7, 2023	Reimbursement Review		Complete	SR0731-000
Melanoma	Final Report	Feb 6, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0022-000
Differentiated Thyroid Carcinoma	Final Report	Feb 6, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0021-000
Specialized Clinics and Health Care Professional Resources for Post–COVID-19 Condition in Canada	Specialized Clinics and Health Care Professional Resources for Post–COVID-19 Co…	Feb 6, 2023	Health Technology Review	Environmental Scan	Completed	ES0372-000
lutetium oxodotreotide	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 1, 2023	Reimbursement Review		Complete	PC0284-000
Wait List Strategies for CT and MRI	Wait List Strategies for CT and MRI	Jan 31, 2023	Health Technology Review	Technology Review	Completed	CM0002-000 - HC0052-000
maribavir	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	SR0720-000
abrocitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	SR0686-000
cabozantinib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	PC0287-000
trastuzumab deruxtecan	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	PC0285-000
CADTH Pharmaceutical Reviews Update — Issue 33		Jan 26, 2023	Reimbursement Review	Pharmaceutical Review Update
empagliflozin	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 24, 2023	Reimbursement Review		Complete	SR0726-000
Drug Safety and Effectiveness Data Access	Report - Drug Safety and Effectiveness Data Access	Jan 20, 2023	Health Technology Review	Technology Review	Completed	HC0029-000
Olaparib (Lynparza) for metastatic castration-resistant prostate cancer - Details	10223OlaparibmCRPC_fnRec_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnEGR_NOREDACT-ABBREV_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnCGR_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_inRec_approvedbyChair_REDACT_Post01Apr2021_final.pdf 10223OlaparibmCRPC_PAGFeedback_EC21Apr2021_final_Redacted.pdf 10223OlaparibmCRPC_SponsorFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_ClinicianFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Patient COI_CCSN_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Combined Clinician COI_EC21Apr2021_final_Redacted.pdf	Jan 20, 2023	Reimbursement Review		Complete	PC0223-000
RET fusion-positive non-small cell lung cancer		Jan 18, 2023	Reimbursement Review	Provisional Funding Algorithm	Withdrawn	PH0020-000
ruxolitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jan 18, 2023	Reimbursement Review		Complete	SR0688-000
HER2-Positive Metastatic Breast Cancer	Final Report	Jan 16, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0006-000
Post‒COVID-19 Condition: A Condition-Level Review	Post-COVID 19 Condition (Long COVID) Scoping Summary	Jan 15, 2023	Health Technology Review	Condition Level Review	Completed	HL0001-000
Identifying Overused Lab Tests in Hospital Settings: A Delphi Study	Identifying Overused Lab Tests in Hospital Settings: A Delphi Study	Jan 13, 2023	Health Technology Review	Environmental Scan	Completed	ES0362-000
HER2 Positive Metastatic Breast Cancer	HER2 Positive Metastatic Breast Cancer - Final Report	Jan 13, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0016-000
faricimab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 13, 2023	Reimbursement Review		Complete	SR0729-000
Metastatic Urothelial Carcinoma	Final Report	Jan 11, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0017-000
Renal Cell Carcinoma	Final Report	Jan 11, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0019-000
Copper and Ceruloplasmin Tests for Children With Global Developmental Delay and Intellectual Disability	Copper and Ceruloplasmin Tests for Children With Global Developmental Delay and…	Jan 9, 2023	Health Technology Review	Rapid Review	Completed	RC1467-000